Acorafloxacin (hydrochloride)

Acorafloxacin (hydrochloride)

• CAS Number: 1001162-01-1
• UNSPSC Description: Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia[1]. Acorafloxacin hydrochloride (Avarofloxacin ) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value[2]. Acorafloxacin hydrochloride (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections[3].
• Target Antigen: Bacterial
• Type: Reference compound
• Related Pathways: Anti-infection
• Field of Research: Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/acorafloxacin-hydrochloride.html
• Solubility: 10 mM in DMSO
• Smiles: COC1=C2N(C3CC3)C=C(C(C2=CC(F)=C1N4C/C(CCC4)=C(F)\CN)=O)C(O)=O.Cl
• Molecular Weight: 455.88
• References & Citations: [1]Jones TM, et al. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.|[2]Kocsis B, et al. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May 23;15(1):34.|[3]Farrell DJ, et al. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011 Jul;55(7):3631-4.
• Shipping Conditions: Room temperature
• Clinical Information: Phase 2